OTA 2023: TXA on Blood Loss & Transfusion Rates for Extracapsular Hip Fractures .
Tranexamic Acid Administered at Time of Hospital Admission Does Not Decrease Transfusion Rates or Blood Loss for Extracapsular Hip Fractures: A Double-Blinded Randomized Clinical Trial
128 patients with AO/OTA 31-A fractures were randomized to receive either intravenous tranexamic acid (IV TXA; n=64), or IV saline (n=64). The primary outcome of interest was rate of red blood cell (RBC) transfusion on postoperative days (POD) 1-4. Secondary outcomes of interest included estimated blood loss, venous thromboembolic events (VTEs), stroke, myocardial infarction, all-cause 90-day readmissions, and all-cause mortality, all measured at 6 months. There were no differences between the two groups in all outcomes.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
